Minnelide is under clinical development by Minneamrita Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Minnelide’s likelihood of approval (LoA) and phase transition for Metastatic Adenocarcinoma of The Pancreas took place on 28 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Minnelide Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Minnelide is under development for the treatment of gastrointestinal tumor, breast cancer, metastatic adenocarcinoma of the pancreas, hepatocellular carcinoma, malignant mesothelioma, non-small cell lung carcinoma, relapsed and refractory acute myeloid leukemia, gastric cancer and EGFR mutated non-small cell lung cancer. It is administered through intravenous and oral routes. The drug candidate is a water soluble analogue of triptolide and is derived from the thunder God vine (Tripterygium wilfordii). It acts by targeting heat shock protein70 (Hsp70). It was also under development for the treatment of epithelial ovarian cancer, neuroblastoma and osteosarcoma.
Quick View Minnelide LOA Data
|Highest Development Stage|